Hirten, Robert P.
Lin, Kai-Chun
Whang, Jessica
Shahub, Sarah
Helmus, Drew
Muthukumar, Sriram
Sands, Bruce E.
Prasad, Shalini
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (K23DK129835)
Crohn's and Colitis Foundation (695759)
Article History
Received: 27 November 2023
Accepted: 1 February 2024
First Online: 3 February 2024
Competing interests
: RPH has served on advisory boards for Bristol Myers Squibb. BES has served as a consultant or received speaker’s fees from AbbVie, Abivax, Adiso Therapeutics, Alimentiv, Amgen, Arena Pharmaceuticals, Artizan Biosciences, Artugen Therapeutics, AstraZeneca, Bacainn Therapeutics, Biora Therapeutics, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Calibr, Celltrion Healthcare, ClostraBio, Connect Biopharm, Cytoki Pharma, Eli Lilly and Company, Entera, Evommune, Ferring, Fresenius Kabi, Galapagos, Gilead, Genentech, Glaxo SmithKline, Gossamer Bio, HMP Acquisition, Imhotex, Immunic, InDex Pharmaceuticals, Innovation Pharmaceuticals, Inotrem, Ironwood Pharmaceuticals, Janssen, Johnson & Johnson, Kaleido, Kalyope, Merck, MiroBio, Morphic Therapeutic, MRM Health, OSE Immunotherapeutics, Pfizer, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Q32 Bio, RedHill Biopharma, Sun Pharma Global, Surrozen, Synlogic Operating Company, Takeda, Target RWE, Theravance Biopharma R&D, TLL Pharmaceutical, USWM Enterprises, Ventyx Biosciences, Viela Bio, and stock options from Ventyx Biosciences. KCL declares no relevant conflicts of interest. JW declares no relevant conflicts of interest. SS declares no relevant conflicts of interest. DH declares no relevant conflicts of interest. SM reports a significant interest in EnLiSense LLC, a company that may have a commercial interest in the results of this research and technology. SP reports a significant interest in EnLiSense LLC, a company that may have a commercial interest in the results of this research and technology.